Shahida Din
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shahida Din has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Esha Sharma
Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, UK
1 shared publication - Jimmy Limdi
Manchester Academic Health Sciences Faculty of Biology, Medicine & Health, University of Manchester, Manchester BL9 7TD, UK
1 shared publication - Kamal Patel
Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, London SW17 0QT, UK
1 shared publication - Laura White
Department of Gastroenterology, London Northwest University Healthcare Trust, London SW17 0QT, UK
1 shared publication - Sailish Honap
Department of Gastroenterology, St George’s University Hospitals NHS Foundation Trust, London, UK
1 shared publication
Latest Publications
- Open Access
- 28 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6667
Guselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning
Guselkumab is a monoclonal antibody directed against the p19 subunit of interleukin-23 (IL-23), thereby preventing IL-23 binding to the IL-23 receptor. IL-23 is a key driver of immune dysregulation and chronic inflammation in inflammatory bowel disease (IBD), making selective IL-23 inhibition an established therapeutic strategy in both Crohn’s disease and ulcerative colitis. Guselkumab is the most recently approved IL-23p19 inhibitor for the treatment of both major forms of IBD. It is the first IL-23p19 inhibitor to offer a fully subcutaneous induction regimen, and preliminary phase III data has suggested potential benefits for patients with perianal Crohn’s disease. In registrational trials, there were significant improvements across multiple clinical and endoscopic endpoints in comparison to ustekinumab, although these trials were not powered for formal superiority testing. This narrative review summarises the biological rationale for IL-23 blockade, reviews the available clinical evidence, discusses practical considerations for its use, and considers its place in the landscape of IBD treatments.
- 28 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6667
Open AccessGuselkumab in Inflammatory Bowel Disease: Mechanism, Clinical Efficacy, Safety, and Treatment Positioning
Guselkumab is a monoclonal antibody directed against the p19 subunit of interleukin-23 (IL-23), thereby preventing IL-23 binding to the IL-23 receptor. IL-23 is a key driver of immune dysregulation and chronic inflammation in inflammatory bowel disease (IBD), making selective IL-23 inhibition an established therapeutic strategy in both Crohn’s disease and ulcerative colitis. Guselkumab is the most recently approved IL-23p19 inhibitor for the treatment of both major forms of IBD. It is the first IL-23p19 inhibitor to offer a fully subcutaneous induction regimen, and preliminary phase III data has suggested potential benefits for patients with perianal Crohn’s disease. In registrational trials, there were significant improvements across multiple clinical and endoscopic endpoints in comparison to ustekinumab, although these trials were not powered for formal superiority testing. This narrative review summarises the biological rationale for IL-23 blockade, reviews the available clinical evidence, discusses practical considerations for its use, and considers its place in the landscape of IBD treatments.